Pre-diabetes and COVID-19, could we be missing the silent killer?

Sosibo, Aubrey Mbulelo; Khathi, Andile

doi:10.1177/1535370220973451

Cited by 13 publications

(15 citation statements)

References 13 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is insufficient information showing the course of the disease in patients with impaired fasting glucose (IFG) and newly diagnosed diabetes. 5 …”

Section: Introductionmentioning

confidence: 99%

COVID-19 Pneumonia in Patients with Impaired Fasting Glucose, Newly Diagnosed Diabetes and Pre-Existing Diabetes: A Tertiary Center Experience

Böyük

Akın²,

Aladağ³

et al. 2022

Journal of Investigative Medicine

View full text Add to dashboard Cite

COVID-19 infection is known to increase mortality in patients with diabetes. We aim to demonstrate the differences in disease course and clinical outcomes of patients with COVID-19 regarding the presence of impaired fasting glucose, pre-existing diabetes mellitus (DM) or new-onset DM. 236 patients with positive reverse transcription-PCR tests for SARS-CoV-2 were included in this single-center, retrospective observational study between March 2020 and May 2021. Laboratory results, comorbidities, medications and imaging findings were noted. Logistic regression was used to estimate associated factors for admission to the intensive care unit (ICU). 43 patients with normal glucose, 53 with impaired fasting glucose, 60 with newly diagnosed DM, and 80 with pre-existing DM were classified. Patients with pre-existing DM had higher fasting glucose and glycated hemoglobin than the other groups (p<0.001 for all). Patients with newly diagnosed DM were more likely to need dexamethasone 6 mg (p=0.001). In both newly diagnosed diabetes and impaired fasting glucose groups, 250 mg methylprednisolone was needed at higher rates (p=0.002). Newly diagnosed DM had higher rates of intubation (21.6%) and more mortality (20.0%) (p=0.045 and p=0.028, respectively). Mortality and hospitalization in the ICU were lower in the group receiving antidiabetic treatment. The risk of ICU attendance was higher in patients with impaired fasting glucose (HR=1.71, 95% CI: 0.48 to 6.08) and newly diagnosed DM (HR=1.88, 95% CI: 0.57 to 6.17), compared with pre-existing DM and non-diabetics. Newly diagnosed DM and impaired fasting glucose are associated with increased mortality and intubation in inpatients with COVID-19.

show abstract

“…There is insufficient information showing the course of the disease in patients with impaired fasting glucose (IFG) and newly diagnosed diabetes. 5 …”

Section: Introductionmentioning

confidence: 99%

COVID-19 Pneumonia in Patients with Impaired Fasting Glucose, Newly Diagnosed Diabetes and Pre-Existing Diabetes: A Tertiary Center Experience

Böyük

Akın²,

Aladağ³

et al. 2022

Journal of Investigative Medicine

View full text Add to dashboard Cite

show abstract

“…Аналогичные нарушения имеются и у пациентов с предиабетом даже на фоне более мягкой гипергликемии. Фенотип предиабета характеризуется наличием хронического системного воспаления низкой степени активности (зафиксировано повышение уровней С-реактивного белка, интерлейкина-6), нарушений механизмов врожденного иммунитета и адаптивного иммунного ответа в ответ на инфекцию, прокоагулянтным состоянием, хотя и в меньшей степени, чем СД2 [36,37]. В этой связи еще в ноябре 2020 г.…”

Section: предиабет и Covid-19unclassified

“…В этой связи еще в ноябре 2020 г. A. Sosibo et al поставили перед нами в своей публикации важнейший вопрос: «Предиабет и COVID-19, не упускаем ли мы тихого убийцу?» [37].…”

Section: предиабет и Covid-19unclassified

“…ангио тензинпревращающего фермента 2-го типа (АПФ-2), которые высоко экспрессированы на клетках островков Лангерганса поджелудочной железы. Вызванное SARS-CoV2 цитотоксическое повреждение бета-клеток поджелудочной железы может привести к усугублению имеющейся дисфункции и развитию высокой стойкой гипергликемии у пациентов с предиабетом в анамнезе [37]. Таким образом, СOVID-19 может стать новым фактором риска развития СД2 наряду с другими, уже хорошо известными.…”

Section: Comorbid Patientunclassified

See 1 more Smart Citation

Prediabetes. A new paradigm for early prevention of cardiovascular disease

Demidova

Plakhotnyaya

2021

Medicinskij sovet

View full text Add to dashboard Cite

This literature review focuses on the association of prediabetes with cardiovascular disease (CVD). Recently, much attention has been paid to the study of prediabetes due to its extremely high prevalence and strong association with a high risk of developing serious complications that worsen the quality of kife of patients. Prediabetes is not only a metabolic condition with a high risk of developing type 2 diabetes mellitus (T2DM), but also CVD and death from all causes. This association is true for both patients who do not yet have CVD and those with a history of CVD. Also during the COVID-19 pandemic, attention is drawn to the fact that people with prediabetes have a higher risk of a severe course of infection, complications and a worse prognosis of the disease. This is associated with hyperglycemia, the presence of chronic systemic inflammation of a low degree of activity, impaired immune response mechanisms and a procoagulant state in patients with prediabetes, although these disorders are less developed than in patients with T2DM. Therefore, early screening of early disorders of normal metabolism. Since active early intervention at the stage of prediabetes helps to prevent the development of type 2 diabetes and CVD.

show abstract

“…Prediabetes is associated with increased CRP and IL-6, and hospitalized patients with moderate to severe COVID-19 infection have been noted to have prediabetes, hence it has been proposed that pre-diabetes be treated as a comorbidity for COVID-19 infection [34]. Whether screening of all COVID-19 infected patients for prediabetes to improve patient care is feasible or beneficial remains to be seen as there is currently no therapeutic drug approved for prediabetes.…”

Section: Prediabetesmentioning

confidence: 99%

COVID-19 and Type 2 Diabetes Mellitus

Mallik¹,

Huda²

2021

Fighting the COVID-19 Pandemic

View full text Add to dashboard Cite

COVID-19 pandemic caused by SARS-COV-2 virus has evolved into a global crisis and is a major concern especially for the diabetes community. People with diabetes mellitus have increased morbidity and mortality associated with COVID-19 infection. Conversely, COVID-19 infection and treatment may predispose to hyperglycemia. Potentially modifiable risk factors have been discussed and urgent need to mitigate the risks is warranted. In this book chapter we summarize the available evidence on COVID-19 and type 2 diabetes mellitus including link between COVID-19 and type 2 diabetes, pathophysiology, clinical manifestations, management and complications.

show abstract

Pre-diabetes and COVID-19, could we be missing the silent killer?

Cited by 13 publications

References 13 publications

COVID-19 Pneumonia in Patients with Impaired Fasting Glucose, Newly Diagnosed Diabetes and Pre-Existing Diabetes: A Tertiary Center Experience

COVID-19 Pneumonia in Patients with Impaired Fasting Glucose, Newly Diagnosed Diabetes and Pre-Existing Diabetes: A Tertiary Center Experience

Prediabetes. A new paradigm for early prevention of cardiovascular disease

COVID-19 and Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About